New treatments in inflammatory bowel disease

Salicylates and steroids remain the mainstay of treatment for inflammatory bowel disease. New formulations which attempt to lower the rates of side effects are under evaluation. The value of azathioprine has been established in ulcerative colitis and cyclosporin has been shown to be of value. Dietary therapy in Crohn's disease has been the focus of a large amount of research and benefits have been demonstrated. New therapies including bioengineered drugs are anticipated.